Barbara Haley

7.7k total citations · 2 hit papers
56 papers, 2.9k citations indexed

About

Barbara Haley is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Barbara Haley has authored 56 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 20 papers in Cancer Research. Recurrent topics in Barbara Haley's work include Breast Cancer Treatment Studies (15 papers), HER2/EGFR in Cancer Research (12 papers) and Advanced Breast Cancer Therapies (11 papers). Barbara Haley is often cited by papers focused on Breast Cancer Treatment Studies (15 papers), HER2/EGFR in Cancer Research (12 papers) and Advanced Breast Cancer Therapies (11 papers). Barbara Haley collaborates with scholars based in United States, Spain and Canada. Barbara Haley's co-authors include Eugene P. Frenkel, David Euhus, Marilyn Leitch, Dorothee Herlyn, Jonathan W. Uhr, Sanjay Shete, Songdong Meng, Nancy Lane, Jianqiang Wang and Leon W.M.M. Terstappen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Cancer.

In The Last Decade

Barbara Haley

54 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Circulating Tumor Cells in Patients with Breast Cancer Dormancy

2004 778 citations Eugene P. Frenkel, Marilyn Leitch et al. Clinical Cancer Research profile →
Nanoparticles for drug delivery in cancer treatment

2008 596 citations Barbara Haley, Eugene P. Frenkel profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Barbara Haley United States	21	1.7k	912	759	629	431	56	2.9k
Jae Hong Seo South Korea	27	1.6k 0.9×	818 0.9×	859 1.1×	523 0.8×	177 0.4×	142	3.1k
Joachim Drevs Germany	29	1.1k 0.7×	757 0.8×	2.0k 2.7×	631 1.0×	300 0.7×	75	3.4k
Michael H. Muders Germany	30	904 0.5×	502 0.6×	1.3k 1.7×	554 0.9×	395 0.9×	79	2.7k
Jasgit C. Sachdev United States	23	1.6k 0.9×	947 1.0×	1.7k 2.3×	558 0.9×	285 0.7×	126	3.4k
Fumiaki Koizumi Japan	35	1.5k 0.9×	887 1.0×	1.9k 2.4×	918 1.5×	459 1.1×	109	3.9k
Moshe Inbar Israel	28	1.7k 1.0×	456 0.5×	669 0.9×	975 1.6×	549 1.3×	171	3.7k
Jean‐Louis Merlin France	30	963 0.6×	599 0.7×	974 1.3×	828 1.3×	586 1.4×	154	2.7k
Holly E. Barker United Kingdom	16	1.7k 1.0×	839 0.9×	1.8k 2.4×	789 1.3×	619 1.4×	27	3.9k
Vuong Trieu United States	23	2.0k 1.1×	889 1.0×	1.2k 1.6×	581 0.9×	565 1.3×	92	4.1k
Christian Dittrich Austria	33	1.6k 0.9×	664 0.7×	1.4k 1.9×	833 1.3×	240 0.6×	136	4.0k

Countries citing papers authored by Barbara Haley

Since Specialization

Citations

This map shows the geographic impact of Barbara Haley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Haley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Haley more than expected).

Fields of papers citing papers by Barbara Haley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Haley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Haley. The network helps show where Barbara Haley may publish in the future.

Co-authorship network of co-authors of Barbara Haley

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Haley. A scholar is included among the top collaborators of Barbara Haley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara Haley. Barbara Haley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Beaudry, Rhys I., Mark J. Haykowsky, James P. MacNamara, et al.. (2022). Cardiac mechanisms for low aerobic power in anthracycline treated, older, long-term breast cancer survivors. Cardio-Oncology. 8(1). 8–8. 7 indexed citations

Chandra, Alvin, Ambarish Pandey, Mujeeb Basit, et al.. (2021). Electronic Health Records–Based Cardio-Oncology Registry for Care Gap Identification and Pragmatic Research: Procedure and Observational Study. JMIR Cardio. 5(1). e22296–e22296. 4 indexed citations

Haley, Barbara, Kiran Batra, Sunati Sahoo, et al.. (2021). A Phase I/Ib Trial of PD 0332991 (Palbociclib) and T-DM1 in HER2-Positive Advanced Breast Cancer After Trastuzumab and Taxane Therapy. Clinical Breast Cancer. 21(5). 417–424. 16 indexed citations

Rahimi, Asal, Osama Mohamad, Kevin Albuquerque, et al.. (2019). Novel hyaluronan formulation for preventing acute skin reactions in breast during radiotherapy: a randomized clinical trial. Supportive Care in Cancer. 28(3). 1481–1489. 9 indexed citations

Kobayashi, Masato, Jin-Sung Chung, Muhammad Shaalan Beg, et al.. (2018). Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the In Vitro Integrity of T Cells from Cancer Patients. Clinical Cancer Research. 25(2). 828–838. 46 indexed citations

Kornblum, Noah, Fengmin Zhao, Judith Manola, et al.. (2018). Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. Journal of Clinical Oncology. 36(16). 1556–1563. 141 indexed citations

Rethorst, Chad D., Heidi Hamann, Thomas Carmody, et al.. (2018). The Promoting Activity in Cancer Survivors (PACES) trial: a multiphase optimization of strategy approach to increasing physical activity in breast cancer survivors. BMC Cancer. 18(1). 744–744. 7 indexed citations

Knudsen, Erik S., Arthur E. Frankel, Joe Y. Chang, Agnieszka K. Witkiewicz, & Barbara Haley. (2017). Palbociclib in combination with TDM1 for metastatic HER2+ breast cancer. Annals of Oncology. 28. i7–i7. 2 indexed citations

Thomas, K., Roshni Rao, Abu Minhajuddin, et al.. (2017). Constructing a Clinicopathologic Prognostic Model for Triple-Negative Breast Cancer. 13(1). 3 indexed citations

10.

Rahimi, Asal, K. Thomas, Ann Spangler, et al.. (2017). Preliminary Results of a Phase 1 Dose-Escalation Trial for Early-Stage Breast Cancer Using 5-Fraction Stereotactic Body Radiation Therapy for Partial-Breast Irradiation. International Journal of Radiation Oncology*Biology*Physics. 98(1). 196–205.e2. 49 indexed citations

11.

Rao, Roshni, Aeisha Rivers, Asal Rahimi, et al.. (2016). Genetic Ancestry using Mitochondrial DNA in patients with Triple‐negative breast cancer (GAMiT study). Cancer. 123(1). 107–113. 6 indexed citations

12.

Thomas, K., Asal Rahimi, Roshni Rao, et al.. (2016). Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients. Breast Cancer Research and Treatment. 161(3). 463–471. 31 indexed citations

13.

Sarode, Venetia, Alana Christie, Rebecca Collins, et al.. (2015). Evaluation of HER2/neu Status by Immunohistochemistry Using Computer-Based Image Analysis and Correlation With Gene Amplification by Fluorescence In Situ Hybridization Assay: A 10-Year Experience and Impact of Test Standardization on Concordance Rate. Archives of Pathology & Laboratory Medicine. 139(7). 922–928. 20 indexed citations

14.

Tripathy, Debu, A. Jo Chien, Nola M. Hylton, et al.. (2015). Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor MK-2206: Graduation results from the I-SPY 2 Trial.. Journal of Clinical Oncology. 33(15_suppl). 524–524. 23 indexed citations

15.

Knudsen, Erik S., et al.. (2014). Targeting CDK4/6 in Her2 Positive Breast Cancer: Therapeutic Effect, Markers, and Combination Strategies. Annals of Oncology. 25. i21–i21. 6 indexed citations

16.

Brufsky, Adam, Linda D. Bosserman, Barbara Haley, et al.. (2009). Zoledronic Acid Effectively Prevents Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results. Clinical Breast Cancer. 9(2). 77–85. 166 indexed citations

17.

Frenkel, Eugene P., Yu‐Min Shen, & Barbara Haley. (2005). The Direct Thrombin Inhibitors: Their Role and Use for Rational Anticoagulation. Hematology/Oncology Clinics of North America. 19(1). 119–145. 9 indexed citations

18.

Sharma, Suash, Hossein Saboorian, William H. Frawley, et al.. (2004). MIB1 Labeling Index as an Indicator of Chemoresponse in Carcinoma of the Breast. Applied immunohistochemistry & molecular morphology. 12(4). 290–295. 7 indexed citations

19.

Wang, Sijian, M. Hossein Saboorian, Eugene P. Frenkel, et al.. (2002). Aneusomy 17 in Breast Cancer: Its Role in HER-2/neu Protein Expression and Implication for Clinical Assessment of HER-2/neu Status. Modern Pathology. 15(2). 137–145. 111 indexed citations

20.

Haley, Barbara, et al.. (1996). Assessing problem feeding behaviors in mid-stage Alzheimer's disease. Geriatric Nursing. 17(2). 63–67. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact